Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y1 receptor antagonist

European Journal of Pharmacology

Volumn 590, Issue 1-3, 2008, Pages 224-232

  Antal Zimanyi, Ildiko ^a   Bruce, Marc A ^b   LeBoulluec, Karen L ^a   Iben, Lawrence G ^a   Mattson, Gail K ^a   McGovern, Rachel T ^a   Hogan, John B ^a   Leahy, Christina L ^c   Flowers, Sharon C ^d   Stanley, Jennifer A ^e   Ortiz, Astrid A ^f   Poindexter, Graham S ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b ARENA PHARMACEUTICALS   (United States)

^c PSYCHOGENICS INC   (United States)

^d PFIZER INC   (United States)

^e Helicon Therapeutics Inc   (United States)

^f BAYER CORPORATION   (United States)

Author keywords

Energy homeostasis; Neuropeptide Y; Neuropeptide Y1 receptor antagonist; Obesity

Indexed keywords

1,4 DIHYDRO [3 [[[[3 [4 (3 METHOXYPHENYL) 1 PIPERIDINYL]PROPYL]AMINO]CARBONYL]AMINO]PHENYL] 2,6 DIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; ANOREXIGENIC AGENT; BMS 193885; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; PEPTIDE YY; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FOOD INTAKE; HUMAN; HUMAN CELL; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT GAIN;

ANIMALS; APPETITE DEPRESSANTS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DIHYDROPYRIDINES; EATING; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROPEPTIDE Y; PHENYLUREA COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y;

EID: 48049095937     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.032     Document Type: Article

References (39)

1. Balasubramaniam A., Joshi R., Su C., Friend L.A., and James J.H. Neuropeptide Y (NEUROPEPTIDE Y) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: combined anorectic effects of Y2 and Y4 receptor-selective agonists. Peptides 28 (2007) 235-240
2. Baldock P.A., Allison S., McDonald M.M., Sainsbury A., Enriquez R.F., Little D.G., Eisman J.A., Gardiner E.M., and Herzog H. Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J. Bone Miner. Res. 21 (2006) 1600-1607
3. Ballinger A. Orlistat in the treatment of obesity. Expert Opin. Pharmacother. 1 (2000) 841-847
4. Bifulco M., Grimaldi C., Gazzerro P., Pisanti S., and Santoro A. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol. Pharmacol. 71 (2007) 1445-1456
5. Boggiano M.M., Chandler P.C., Oswald K.D., Rodgers R.J., Blundell J.E., Ishii Y., Beattie A.H., Holch P., Allison D.B., Schindler M., Arndt K., Rudolf K., Mark M., Schoelch C., Joost H.G., Klaus S., Thone-Reineke C., Benoit S.C., Seeley R.J., Beck-Sickinger A.G., Koglin N., Raun K., Madsen K., Wulff B.S., Stidsen C.E., Birringer M., Kreuzer O.J., Deng X.Y., Whitcomb D.C., Halem H., Taylor J., Dong J., Datta R., Culler M., Ortmann S., Castaneda T.R., and Tschop M. PYY3-36 as an anti-obesity drug target. Obes. Rev. 6 (2005) 307-322
6. Brown M., Bing C., King P., Pickavance L., Heal D., and Wilding J. Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. Br. J. Pharmacol. 132 (2001) 1898-1904
7. Diop L., Briere R., Grondin L., and Reader T.A. Adrenergic receptor and catecholamine distribution in rat cerebral cortex: binding studies with [3H]prazosin, [3H]idazoxan and [3H]dihydroalprenolol. Brain Res. 402 (2003) 403-408
8. Gehlert D.R. Multiple receptors for the pancreatic polypeptide (PP-Fold) family: physiological implications. Proc. Soc. Exp. Biol. Med. 218 (1998) 7-22
9. Gehlert D.R. Introduction to the reviews on neuropeptide Y. Neuropeptides 38 (2004) 135-140
10. 3 receptor-mediated synaptic inhibition by chimeric neuropeptide Y-peptide YY peptides in the rat brainstem. Br. J. Pharmacol. 120 (1997) 481-487
11. Heilig M. The neuropeptide Y system in stress, anxiety and depression. Neuropeptides 38 (2004) 213-224
12. Huang X.F., Xin X., McLennan P., and Storlien L. Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression. Diabetes Obes. Metab. 6 (2004) 35-44
13. Hutchinson N.I., and Ryder S.W. Obesity pharmacotherapy from a regulatory perspective: overview and key challenges. Clin. Pharmacol. Ther. 81 (2007) 756-760
14. Jarbe T.U.C., Harris M.Y., Li C., Liu Q., and Makriyannis A. Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. Psychopharmacol. 177 (2004) 35-45
15. Jarrahian A., and Hillard C.J. Arachidonylethanolamide (anadamide) binds with low affinity to dihydropyridine binding sites in brain membrane. Prostaglandins Leukot. Essent. Fat. Acids 57 (1997) 551-554
16. Kanatani A., Ishihara A., Asahi S., Tanaka T., Ozaki S., and Ihara M. Potent neuropeptide Y Y1 receptor antagonist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake. Endocrinology 137 (1996) 3177-3182
17. Kanatani A., Kanno T., Ishihara A., Hata M., Sakuraba A., Tanaka T., Tsuchiya Y., Mase T., Fukuroda T., Fukami T., and Ihara M. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem. Biophys. Res. Commun. 266 (1999) 88-91
18. Kask A., Rago L., and Harro J. Anxiogenic-like effect of the neuropeptide Y Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Reg. Peptides 75-76 (1998) 255-262
19. Kojima S., Ueno N., Asakawa A., Sagiyama K., Naruo T., Mizuno S., and Inui A. A role for pancreatic polypeptide in feeding and body weight regulation. Peptides 28 (2007) 459-463
20. Larhammar D., Blomqvist A.G., and Soderberg C. Evolution of neuropeptide Y and its related peptides. Comp. Biochem. Physiol., C 106 (1993) 743-752
21. Leibowitz S.F., Sladek C., Spencer L., and Tempel D. Neuropeptide Y, epinephrine and norepinephrine in the paraventricular nucleus: stimulation of feeding and the release of corticosterone, vasopressin and glucose. Brain Res. Bull. 21 (1988) 905-912
22. Lin S., Boey D., and Herzog H. Neuropeptide Y and Y receptors: Lessons from transgenic and knockout models. Neuropeptides 38 (2004) 189-200
23. 4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity. Endocrinology 147 (2006) 5094-5101
24. 5 neuropeptide Y receptor in feeding and obesity. Nat. Med. 4 (1998) 718-721
25. 1 receptor antagonist BIBP 3226 blocks neuropeptide Y induced feeding via a non-specific mechanism. Reg. Peptides 75-76 (1998) 377-382
26. Park A., and Bloom S.R. Peptides and obesity: the PYY3-36 story. Re. Peptides 119 (2004) 1-2
27. 1 receptor knockouts. Neuropeptides 38 (2004) 267-275
28. 1 receptor. Nat. Med. 4 (1998) 722-726
29. 1 receptor antagonists 2. bioisosteric urea replacements. Bioorg. Med. Chem. 12 (2004) 507-521
30. Poindexter G.S., Bruce M.A., LeBoulluec K.L., Monkovic I., Martin S.W., Parker E.M., Iben L.G., McGovern R.T., Ortiz A.A., Stanley J.A., Mattson G.K., Kozlowski M., Arcuri M., and Antal-Zimanyi I. Dihydropyridine neuropeptide Y Y(1) receptor antagonists. Bioorg. Med. Chem. Lett. 12 (2002) 379-382
31. Rose P.M., Lynch J.S., Frazier S.T., Fisher S.M., Chung W., Battaglino P., Fathi Z., Leibel R., and Fernandes P. Molecular genetic analysis of a human neuropeptide Y receptor. The human homolog of the murine "Y5" receptor may be a pseudogene. J. Biol. Chem. 272 (1997) 3622-3627
32. 2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8938-8943
33. 4 receptors on adiposity and bone mass revealed in double knockout mice. Mol. Cell. Biol. 23 (2003) 5225-5233
34. 1 receptor deficiency in mice. Diabetes 55 (2006) 19-26
35. Sloth B., Holst J.J., Flint A., Gregersen N.T., and Astrup A. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am. J. Physiol: Endocrinol. Metab. 292 (2007) E1062-E1068
36. 1 receptor antagonist BIBP 3226. J. Pharmacol. Exp. Ther. 275 (1995) 143-149
37. 1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. J. Pharmacol. 125 (1998) 549-555
38. Woldbye D.P., and Kokaia M. Neuropeptide Y and seizures: effects of exogenously applied ligands. Neuropeptides 38 (2004) 253-260
39. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. Can. Med. Assoc. J. 166 (2002) 1307-1308